ReviewArchives of pharmacal research2025
Emerging concepts and challenges in the development of disease-modifying osteoarthritis drugs - a more refined perspective.
Review in Archives of pharmacal research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Multi‑omics integration in osteoarthritis: Unraveling cell‑type‑specific gene‑metabolite networks for precision medicine (Review).International journal of molecular medicine · 2026Review
- Multi-Trajectories of Sleep Disturbance and Depressive Symptoms and Incident Osteoarthritis: Evidence From the English Longitudinal Study of Ageing.Brain and behavior · 2026Article
- Biomimetic cellular sponges for neutralizing inflammatory cytokines in osteoarthritic joints.Materials today. Bio · 2026Article
- Osteoarthritis phenotypes: advancing precision medicine through clinical, structural, and molecular stratification.International orthopaedics · 2026Review
- Systemic implications of osteoarthritis: from local degeneration to systemic metabolic Dysregulation.Journal of translational medicine · 2026Review
- Phytochemicals in arthritis management: insight into pharmacodynamic potency with pharmacokinetic profile.Inflammopharmacology · 2026Review
- Computational Insights into Flavonoids for ADAMTS-5 Exosite Inhibition in Knee Osteoarthritis: Docking, MD Simulations, and Machine Learning-Guided Structure Prediction.Molecules (Basel, Switzerland) · 2026Article
- Bifidobacterium longum CBi0703 lysate modulates oxidative stress induced apoptosis and cartilage related gene expression in SW1353 chondrocytes: in vitro insights into the gut joint axis in Osteoarthritis.Scientific reports · 2026Article
- Epigenetic regulation in osteoarthritis: recent updates and emerging mechanisms.Frontiers in genetics · 2026Review
- Translating Osteoarthritis Genetic Risk Into Biomarkers: Opportunities, Pitfalls, and Implementation Considerations.Human mutation · 2026Review
- Current status and influencing factors of early delayed neurocognitive recovery in older adult patients after major orthopedic surgery under general anesthesia: a cohort study.Frontiers in public health · 2026Observational
- Repurposing the antihistamine cyproheptadine for osteoarthritis: nothing to sneeze at.The Journal of clinical investigation · 2025Article
- Localisation-Dependent Variations in Articular Cartilage ECM: Implications for Tissue Engineering and Cartilage Repair.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Osteoarthritis (OA) is the most common joint disease worldwide. Despite significant efforts byresearchers, no disease-modifying osteoarthritis drugs (DMOADs) have been approved yet. This review compares preclinical and clinical studies of promising therapeutic approaches to gain insights into the potential reasons for their failure in clinical trials. For this purpose, prime examples of different therapeutic groups, including the antioxidant NAC, senotherapeutic UBX0101, anti-inflammatory drug Anakinra®, Wnt inhibitor Lorecevivint®, chondroanabolic growth factor Sprifermin™, and various protease inhibitors, are discussed in detail. The limitations of commonly used OA animal models are elaborated to understand this failure better. Moreover, this review addresses the challenges of patient stratification into different endotypes and phenotypes, the consideration of subgrouping in clinical trials, and the lack of suitable clinical outcome parameters. In summary, this review highlights potential reasons for the high failure rate of DMOADs in clinical trials and outlines key points for future improvement.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.